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Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
have changed the treatment strategy for EGFR-mutant lung cancers; however,
resistance usually occurs due to a secondary mutation, T790M, in EGFR.
Combination therapy using afatinib and cetuximab has had good results in
lung tumors harboring EGFRT790M mutations in clinical trials. The effect of
bevacizumab, an antivascular endothelial growth factor (VEGF) antibody,
combined with EGFR-TKIs has also been investigated. We hypothesized that
the dose of afatinib and cetuximab could be reduced by combination with
bevacizumab and that the triplet therapy may result in better tumor inhibition
with tolerable toxicity. Using a xenograft mouse model with H1975-harboring
EGFRL858R+T790M and RPC-9-harboring EGFR19DEL+T790M, we tested the
efficacy of the triplet therapy with a modified dose of afatinib, cetuximab, and
bevacizumab, and compared this therapy to single and double therapies. Tri-
plet therapy with afatinib, cetuximab, and bevacizumab induced pathological
complete remission in xenograft tumors with H1975 and RPC-9 cells versus
tumors treated with single or double therapies. We saw no body weight loss in
the mice. The triple therapy induced a significant reduction in CD31-positive
vascular endothelial cells and increased cleaved caspase-3-positive cells in the
tumors. This suggests that one mechanism underlying the deep remission
could be suppression of neovascularization and induction of apoptosis by
intensive inhibition of driver oncoproteins and VEGF. These results highlight
the potential of afatinib, cetuximab, and bevacizumab to induce deep remis-
sion in tumors harboring EGFRT790M mutations. Therefore, clinical trials of
this combination therapy are warranted.
Abbreviations
EGFR, epidermal growth factor receptor; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MAPK, mitogen-activated protein
kinase; NSCLC, non-small-cell lung cancer; TKIs, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor.
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1. Introduction
The discovery of oncogenic driver mutations, including
epidermal growth factor receptor (EGFR) mutations,
has dramatically changed our practical strategy for
patients with advanced non-small-cell lung cancer
(NSCLC; Saito et al., 2016). Notably, patients with
driver mutations that received matched targeted agents
lived much longer than those with a driver and no tar-
geted therapy (Kris et al., 2014).
Several randomized clinical trials have shown that
first-generation EGFR tyrosine kinase inhibitors
(TKIs), including gefitinib and erlotinib, and second-
generation EGFR-TKIs, including afatinib, achieved a
good clinical response in lung cancers harboring acti-
vating EGFR mutations (Maemondo et al., 2010;
Yang et al., 2015; Zhou et al., 2011). Of note, afatinib
resulted in prolonged survival compared with platinum
doublet chemotherapy, the first such improvement in
30 years (Yang et al., 2015). However, the majority of
lung tumors acquire resistance to EGFR-TKI, usually
after about 12 months of treatment (Ohashi et al.,
2013). Up to 60% of the lung tumors develop a sec-
ondary resistant mutation, T790M, in exon 20 of
EGFR (Ohashi et al., 2012; Sequist et al., 2011).
Recently, a third-generation EGFR-TKI (osimer-
tinib) that inhibits EGFR T790M has been approved
in several countries, including the USA and Japan.
Unfortunately, resistance to new-generation EGFR-
TKIs is inevitable (J€anne et al., 2015; Planchard et al.,
2015; Thress et al., 2015). As an alternative strategy,
intensive EGFR inhibition combined with afatinib and
a monoclonal anti-EGFR antibody, cetuximab,
showed a promising response in resistant tumors with
EGFR T790M mutations in a phase Ib clinical trial
(Janjigian et al., 2014; Regales et al., 2009). A ran-
domized phase II/III trial is currently being conducted
(NCT02438722); however, considering the results of
the phase Ib trial, the effect of this drug combination
still seems to be transient (Janjigian et al., 2014; Piraz-
zoli et al., 2014).
Antiangiogenic agents are thought to have several
effects on tumors, including normalization of microvas-
culature and improvement of drug delivery (Ferrara
and Kerbel, 2005; Jain, 2013). To further improve the
EGFR-TKI management strategy for lung tumors har-
boring EGFR mutations, we established a combination
therapy that includes EGFR-TKIs and an antivascular
endothelial growth factor (VEGF) antibody, beva-
cizumab, to treat lung cancer tumors harboring EGFR
T790M mutations in vivo (Ichihara et al., 2009; Nino-
miya et al., 2013). Subsequently, the effect of
combination therapy was assessed in treatment-na€ıve
patients in clinical trials. In a randomized phase II trial,
the erlotinib and bevacizumab combination signifi-
cantly prolonged progression-free survival compared to
erlotinib alone in patients with lung cancers harboring
EGFR mutations (Seto et al., 2014). We also reported
the promising effect of combination therapy using gefi-
tinib and bevacizumab (Ichihara et al., 2015), and we
are currently conducting a phase I/II clinical trial on
the combination of afatinib and bevacizumab in the
same population (UMIN000015944).
Taken together, we hypothesized that the addition
of bevacizumab to the afatinib and cetuximab combi-
nation may allow for modification of the dose for each
of the agents, resulting in better tumor inhibition and
more tolerable toxicity. In this study, we showed that
the triplet therapy, which included afatinib, cetuximab,
and bevacizumab, induced pathological complete
remission (CR) repeatedly in lung cancer cells harbor-
ing EGFR T790M mutations in vivo.
2. Materials and methods
2.1. Cell culture and growth inhibition in vitro
Gefitinib-resistant adenocarcinoma cells (RPC-9) har-
boring EGFR exon 19 deletion mutations (E746-A750)
and exon 20 missense mutations (T790M) were estab-
lished in our laboratory (Ogino et al., 2007). The
H1975 pulmonary adenocarcinoma cells carrying exon
21 missense mutations (L858R) and T790M cells were
purchased from the American Type Culture Collection
(Rockville, MD, USA). Cells were cultured at 37 °C
with 5% CO2 in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum. Growth
inhibition was determined using a modified 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described previously (Ogino et al.,
2007). Each assay was performed in triplicate.
2.2. Reagents and antibodies
Afatinib was kindly provided by Boehringer-Ingelheim
(Ingelheim am Rhein, Germany). Gefitinib, cetuximab,
and bevacizumab were purchased from EVELETH
(Eveleth, MN, USA). Osimertinib was purchased from
Selleck Chemicals (Houston, TX, USA). Rabbit antis-
era against EGFR, phospho-specific (p) EGFR
(pY1068), mitogen-activated protein kinase (MAPK),
pMAPK (pT202/pY204), Akt, pAkt (pSer473), cleaved
caspase-3, BIM, and GAPDH were purchased from
Cell Signaling Technology (Danvers, MA, USA).
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Anti-Ki-67 antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-CD31
antibody was purchased from DIANOVA (Hamburg,
Germany).
2.3. Immunoblotting analysis
Cells and frozen tissues were lysed in a radioimmuno-
precipitation assay buffer [1% Triton X-100, 0.1% SDS,
50 mmolL1 Tris/HCl (pH 7.4), 150 mmolL1 NaCl,
1 mmolL1 EDTA, 1 mmolL1 EGTA, 10 mmolL1
b-glycerol phosphate, 10 mmolL1 NaF, 1 mmolL1
sodium orthovanadate-containing protease inhibitor
tablets (Roche Applied Sciences, Mannheim, Ger-
many)]. Proteins were separated by electrophoresis on
polyacrylamide gels, transferred onto nitrocellulose
membranes, and probed with specific antibodies fol-
lowed by detection with Enhanced Chemiluminescence
Plus (GE Healthcare Biosciences, Piscataway, NJ,
USA).
2.4. Xenograft model
Female athymic mice aged 5–7 weeks were purchased
from Charles River Laboratories Japan (Yokohama,
Japan). All mice were provided with sterilized food and
water and housed in a barrier facility under a 12-hour
light/12-hour dark cycle. Cells (2 9 106) were injected
bilaterally into the backs of the mice. Ten days after
injection, the mice were randomly assigned to a group
and were then treated with either monotherapy, double
therapies, triplet therapy (4–10 mice per group), vehicle
(p.o. five times a week), afatinib (p.o. 10 mgkg1, five
times a week or 25 mgkg1, five times a week), cetux-
imab (i.p. 0.1 mg per mouse, once a week or 1 mg per
mouse, twice a week), bevacizumab (i.p. 2 mgkg1,
twice a week or 5 mgkg1, twice a week), or osimertinib
(p.o. 5 mgkg1, five times a week). Tumor volume
(width2 9 length/2) was determined twice a week. The
administration period for each drug was 28 days, and
the follow-up time was a further 28 days.
2.5. Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks from
the samples were cut to a thickness of 5 lm, placed on
glass slides, and deparaffinized in xylene and graded
alcohol for 10 min. The antigen was incubated in
10 mmolL1 sodium citrate buffer, pH 6.0, for
10 min in a 95 °C water bath. The sections were then
blocked for endogenous peroxidase with 0.3% hydro-
gen peroxide in methanol. The slides were rinsed with
TBS containing 0.1% Tween 20, and the sections were
blocked with goat serum for 60 min. The sections were
incubated with an anti-EGFR monoclonal antibody,
cleaved caspase-3 antibody, Ki-67 antibody, or anti-
mouse CD31 antibody overnight at 4 °C. Then, the
sections were amplified using biotinylated anti-rabbit
antibodies and avidin–biotinylated horseradish peroxi-
dase conjugate for 10 min (LSABTM2 Kit;
DakoCytomation, Glostrup, Denmark), and reacted
with 3,3-diaminobenzidine. Finally, the sections were
counterstained with hematoxylin. Cleaved caspase-3-
and Ki-67-positive cells, and CD31 blood vessels, were
counted in five random fields (9 100).
2.6. Liquid chromatography–tandem mass
spectrometry (LC-MS/MS) conditions for afatinib
quantification
Chromatographic separation was performed using a
high-performance liquid chromatography system (Agi-
lent 1100 series; Agilent, Santa Clara, CA, USA) and a
CAPCELL PAK C18 MGIII S-5 (100 mm 9 2.0 mm;
i.d., 3 lm; SHISEIDO, Tokyo, Japan) analytical col-
umn at 40 °C. The isocratic mobile phase consisted of
mobile phase A (0.1% formic acid) and mobile phase B
(methanol; 40 : 60, v/v) at a flow rate of 0.3 mLmin1.
The solution was filtered using a 0.22-lm membrane.
Mass spectrometric detection was performed on an
AB SCIEX API 2000 triple quadrupole mass spec-
trometer (AB SCIEX, Toronto, ON, Canada). Data
acquisition was performed using AnalystTM 1.6.1 soft-
ware (AB SCIEX). The mass spectrometer was oper-
ated in positive ion mode. Optimized instrument
settings were as follows: curtain gas, 10 psi; ion source
gas 1, 30 psi; ion source gas 2, 50 psi; ion spray volt-
age, 4000 V; and turbo heater temperature, 500 °C.
Quantification was performed in multiple reaction
monitoring mode with mass-to-charge (m/z) transitions
at 486.5 > 371.5 for afatinib.
2.7. Preparation of the standard solution
Stock solutions of standard afatinib were prepared at
1 mgmL1 in methanol. The stock solutions of CP
were diluted to 20, 100, 200, 1000, and 2000 ngmL1
in water.
Xenografts collected from five to seven mice were
weighed (10–30 mg) and homogenized in 200 lL of
water. A mixture of 600 lL of acetonitrile with 0.5%
acetic acid and 50 lL of standard afatinib solution
was added to 200 lL of xenograft homogenate. The
mixture was vortexed for 1 min, kept on ice for
10 min, then centrifuged at 10 390 g for 10 min. An
800 lL aliquot of the supernatant was transferred to a
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clean microtube and evaporated to dryness under vac-
uum at 65 °C for approximately 1 h. The dry extracts
were reconstituted in 100 lL of a mixture of 0.1% for-
mic acid/methanol (20 : 80, v/v) by vortex mixing for
30 s. The samples were centrifuged once more for
10 min at 10 390 g, and 40 lL of the clear supernatant
was injected into the HPLC system. All data are
shown as amounts of afatinib per wet weight of col-
lected xenograft.
2.8. Statistical analysis
Statistical analysis was performed using SPSS (SPSS,
Chicago, IL, USA). Group differences were compared
using Student’s t-test. A P value < 0.05 was considered
statistically significant.
3. Results
3.1. The transient effect of afatinib plus
cetuximab, or afatinib plus bevacizumab, in RPC-
9 xenograft models
We first assessed the magnitude of remission induced by
doublet therapies (afatinib plus cetuximab or afatinib
plus bevacizumab) in RPC-9 xenograft tumors harbor-
ing EGFR exon 19Del and T790M mutations (Ogino
et al., 2007). A previous preclinical study demonstrated
that the combination of afatinib (25 mgkg1, 5 days
per week) with cetuximab (1 mg per mouse, twice a
week) was more effective than each therapy alone in
cells with T790M mutations (Regales et al., 2009). The
same dose of afatinib plus cetuximab was administrated
in a xenograft model using RPC-9 cells for 4 weeks, and
the mice were subsequently observed for 4 weeks after
treatment cessation. As expected, the combination ther-
apy significantly inhibited the xenograft tumors. Nota-
bly, prompt regrowth of tumors was confirmed after
treatment discontinuation (Fig. 1A), and a trend
toward body weight loss was observed in mice treated
with combination therapies (Fig. S1A).
The magnitude of remission induced by afatinib
(10 mgkg1, 5 days per week) and bevacizumab
(5 mgkg1, 2 days per week) (Ninomiya et al., 2013)
combination therapy was also assessed for 4 weeks
during treatment, and a subsequent 4 weeks after
treatment cessation. Again, the combination therapy
significantly inhibited xenograft tumor growth for
RPC-9 cells, but the tumors quickly regrew during the
observation period (Fig. 1B) and body weight loss was
not negligible (Fig. S1B).
Combined, these results show that doublet therapies
had a significant effect on lung cancer cells harboring
EGFR T790M mutations; however, there is room for
improvement in terms of the magnitude of remission
and toxicity.
3.2. The efficacy and safety of mono- and
combination therapies with a modified dose of
afatinib, cetuximab, or bevacizumab
To develop the triplet therapy, we first assessed the
efficacy and safety of modified doses of the monother-
apy of each drugs. A modified dose of afatinib
(10 mgkg1, 5 days per week, n = 6), cetuximab
(0.1 mg per mouse, once a week, n = 6), or beva-
cizumab (2 mgkg1, twice a week, n = 6) was admin-
istrated to the RPC-9 xenograft model mice for
4 weeks. Each monotherapy had only a slight effect on
cell growth (Fig. S2A). Body weight loss was not
observed in any treatment group (Fig. S2B). These
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Fig. 1. Transient effect of afatinib plus cetuximab or afatinib plus
bevacizumab in xenograft tumors with RPC-9 cells harboring
epidermal growth factor receptor (EGFR) exon 19Del + T790M
mutations. Afa, afatinib; Cet, cetuximab; Bev, bevacizumab. (A) The
mice were treated with vehicle or afatinib (25 mgkg1, five times
per week p.o.) plus cetuximab (1 mg per mouse, twice a week
i.p.). Bars, SE. (B) The mice were treated with afatinib
(10 mgkg1, five times per week p.o.) plus bevacizumab
(5 mgkg1, twice a week i.p.). Bars, SE.
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results indicate that the modified monotherapy doses
were tolerable, but that the effect of these therapies
was very limited.
We next tested the combination therapies using the
modified drug doses. Afatinib (10 mgkg1, 5 days per
week) plus cetuximab (0.1 mg per mouse, once a week;
n = 8), afatinib (10 mgkg1, 5 days per week) plus
bevacizumab (2 mgkg1, twice a week; n = 8), or
cetuximab (0.1 mg per mouse, once a week) plus beva-
cizumab (2 mgkg1, twice a week; n = 8) were admin-
istrated to mice harboring RPC-9 xenograft tumors.
No body weight loss was observed in either group
(Fig. S2E,F), but the effect of the combination thera-
pies was still limited (Fig. S2C,D). The tumors in each
group were moderately inhibited during the treatment
period; however, the tumors regrew during the obser-
vation period. Consequently, mono- or combo-thera-
pies using the modified drug doses were tolerable, but
the effect was insufficient to inhibit lung cancer cells
harboring EGFR T790M mutations.
3.3. Pathological complete remission was
induced by triplet therapy with modified doses
of afatinib, cetuximab, and bevacizumab in lung
cancer cells harboring EGFR T790M mutations
To establish a more promising therapy, we sought to
assess the efficacy and safety of triplet therapy using
modified doses of afatinib (10 mgkg1, 5 days per
week), cetuximab (0.1 mg per mouse, once a week),
and bevacizumab (2 mgkg1, twice a week) in vivo.
Surprisingly, the triplet therapy induced CR within the
first 2 weeks in RPC-9 xenograft tumors (Fig. 2A).
Furthermore, the tumors treated with triplet therapy
did not regrow during the four-week observation per-
iod. Notably, no significant body weight loss was
observed in any group (Fig. 2B).
To confirm the remission magnitude, tumors were
enucleated 56 days after drug administration (i.e.,
28 days after discontinuation of the treatment). The
histology of these tumors was first assessed by a
pathologist (T. Yoshino, Okayama University). As
expected, no cancer cells were observed in the tumors
treated with triplet therapy. In contrast, many cancer
cells were observed in the tumors treated with vehicle,
mono-, or combination therapies (Fig. 2C). Total
EGFR immunostaining was also examined as a tumor
marker. No cells with EGFR overexpression were
observed in tumors treated with triplet therapy, while
many cancer cells with EGFR overexpression were
found in the other groups (Fig. 2D). To test cancer
cell viability in each of the tumors, we minced the
tumors that were enucleated from the mice in culture
medium (Fig. S3). Interestingly, no cancer cell lines
could be re-established from the tumors treated with
triplet therapy. In contrast, almost all of the other
tumors could be cultured in the same way as parental
RPC-9 cells (Figs 2E and S3). To confirm deep remis-
sion, the triplet therapy was tested in other lung cancer
cell lines, namely H1975 cells harboring EGFR L858R
and T790M mutations. Mice with H1975 cell xenograft
tumors were treated with the same dose and schedule
as mice with RPC-9 tumors. The triplet therapy
repeatedly induced deep remission in the H1975 cell
xenograft tumors (Fig. 3A–E). Taken together, we
conclude that the triplet therapy may induce deep
remission in lung cancer cells with EGFR T790M
mutations in vivo.
3.4. Mechanisms of deep remission induced by
triplet therapy with modified dose of afatinib,
cetuximab, and bevacizumab
We sought to investigate the mechanisms underlying
the deep remission induced by the triplet therapy.
First, to assess the role of afatinib, an alternative tri-
plet therapy with ‘gefitinib’ instead of afatinib was
administrated to mice with RPC-9 xenograft tumors.
The tumors were only moderately inhibited during the
treatment period, and rapid tumor growth was
observed during the observation period (Fig. 4A).
Apparently, triplet therapy with gefitinib, cetuximab,
and bevacizumab could not induce remission. This
suggests that afatinib plays a crucial role in deep
remission. Second, speculating that the drug concen-
tration may play a role in the induction of deep remis-
sion, we measured the concentration of afatinib in the
tumors treated with triplet therapy. Unexpectedly, the
concentration of afatinib was not significantly
increased in the tumors treated with triplet therapy
compared with afatinib alone or afatinib plus cetux-
imab (Fig. 4B). Considering the results of this experi-
ment, and the fact that intensive doses of afatinib plus
cetuximab did not induce CR (Fig. 1A), we thought
that the concentration of afatinib may not be crucial
to achieve deep remission in our model.
To further investigate the mechanisms of deep
remission in vivo, RPC-9 xenograft tumors were col-
lected after a week of treatment with afatinib alone,
with afatinib and cetuximab, or with triplet therapy.
The EGFR signaling pathway was assessed, and con-
sistent with a previous report, phosphorylation of
EGFR, AKT, and ERK was inhibited to a greater
degree in tumors treated with afatinib and cetuximab
compared to tumors treated with afatinib alone
(Fig. 4C). However, the triplet therapy with afatinib,
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cetuximab, and bevacizumab did not have a superior
inhibitory effect on EGFR signaling compared to afa-
tinib plus cetuximab. This suggests that bevacizumab
had little direct effect on the EGFR signaling pathway.
Next, the expression of CD31 and Ki-67 was examined
through immunostaining to determine neovasculariza-
tion and proliferation, respectively. As expected,
CD31-positive blood vessels were reduced significantly
in tumors treated with triplet therapy compared to
tumors treated with therapies without bevacizumab
(Figs 4D and S4A). The number of Ki-67-positive cells
was also smaller in tumors treated with triplet therapy
compared to those treated with other therapies
(Figs 4E and S4B). We then examined the expression
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Fig. 2. Deep remission induced by triplet therapy in xenograft tumors with RPC-9 cells harboring EGFR exon 19Del + T790M mutations.
Afa, afatinib; Cet, cetuximab; Bev, bevacizumab. (A) RPC-9 cells were inoculated into nude mice and maintained when the tumor volumes
reached 200 mm3. A modified dose of afatinib (10 mgkg1, five times per week p.o.), cetuximab (0.1 mg per body, once a week i.p.), or
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SE. (B) Body weight loss was not observed in the mice. Bars, SE. (C) Microscopic examination of tumor tissues stained by hematoxylin and
eosin. No cancer cells were detected in the tumors treated with the triplet therapy. (D) Immunohistochemistry examination revealed that
cancer cells overexpressing EGFR were not observed in the tumors treated with the triplet therapy. Scale bar = 100 lm. (E) Cell line re-
establishment from xenograft tumors (n = 7). The enucleated tumors were minced and incubated in vitro. The tumors treated with triplet
therapy could not be maintained in vitro.
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of cleaved caspase-3 by immunostaining to determine
the level of apoptosis. The number of tumor cells with
cleaved caspase-3 expression was higher in the tumors
treated with triplet therapy compared with the other
groups (Figs 4F and S4C). Consistent with the result,
the proapoptotic protein BIM was upregulated in the
tumors treated with triplet therapy (Fig. S5). These
results suggest that the greater suppression of neovas-
cularization, the inhibitory effect on cell proliferation,
and the induction of apoptosis by the triplet therapy
may play important roles in the induction of deep
remission in vivo.
4. Discussion
Resistance to EGFR-TKIs is still a critical issue in
EGFR-mutant lung tumors. In this study, we discov-
ered that triple therapy that included afatinib, cetux-
imab, and bevacizumab induced deep remission in
xenograft tumors harboring EGFR T790M mutations.
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1 week with the indicated drugs and collected for analysis. Afa, afatinib (10 mgkg1, five times per week p.o.); Cet, cetuximab (0.1 mg per
body, once a week i.p.); or Bev, bevacizumab (2 mgkg1, twice a week i.p.). (C) The inhibitory effect on the EGFR signaling pathway in
xenograft tumors was assessed by western blot. (D) The percent of CD31-positive cells in the xenograft tumors treated with indicated
drugs. Bars, SE. *P < 0.001. (E) The percent of Ki-67-positive cells in the xenograft tumors treated with indicated drugs. Bars, SE.
*P < 0.001. (F) The percent of cleaved caspase-3-positive cells in the xenograft tumors treated with indicated drugs. Bars, SE. *P < 0.001.
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Earlier and deeper remission correlates with longer
overall survival in Philadelphia chromosome-positive
chronic myeloid leukemia (Hughes et al., 2014). Com-
plete and partial response could also be potential sur-
rogate markers for predicting overall survival in lung
cancer patients with EGFR mutations (Takeda et al.,
2014). Therefore, the fact that we observed deep remis-
sion in response to afatinib, cetuximab, and beva-
cizumab in vivo is important.
Third-generation EGFR-TKI, osimertinib, has
shown good inhibitory effect in resistant lung tumors
harboring EGFR T790M mutations (J€anne et al.,
2015). In this in vivo study, we confirmed the excellent
inhibitory effect of osimertinib on xenograft tumors
with RPC-9 cells harboring EGFR T790M mutations
(Fig. S6). The new compound almost completely inhib-
ited tumor growth in vivo; however, most of the
tumors regrew during the four-week observation per-
iod post-treatment. We also assessed the effect of com-
bination therapy with osimertinib and bevacizumab.
The effect of combination therapy was superior to that
of osimertinib alone; however, most of the tumors
regrew during the observation period (Fig. S6). This
suggests that the inhibitory effect of osimertinib is
excellent, but that the magnitude of remission has
room for improvement. Finally, we also assessed the
influence of preadministering osimertinib before triplet
therapy treatment with afatinib, cetuximab, and beva-
cizumab in a xenograft model of RPC-9 cells. Unfor-
tunately, the effect induced by the triplet therapy
seems to be attenuated in tumors pretreated with
osimertinib for 2 weeks (Fig. S7). This suggests that
the triplet therapy has difficulty overcoming osimer-
tinib resistance in lung cancer harboring EGFR
T790M. This might be explained by the studies that
reported EGFR-independent resistant mechanisms of
osimertinib (e.g., MET amplification or RAS muta-
tion; Kim et al., 2015; Ortiz-Cuaran et al., 2016; Plan-
chard et al., 2015). Alternative triplet therapy with
osimertinib, cetuximab, and bevacizumab may be
worth exploring.
The mechanisms of the deep remission induced by
the triplet therapy may be complicated. The addition
of cetuximab to afatinib (Regales et al., 2009) is one
of the most important factors, as afatinib monother-
apy (Miller et al., 2012), cetuximab monotherapy
(Mukohara et al., 2005), or combinations of erlotinib
and cetuximab (Janjigian et al., 2011), or gefitinib,
cetuximab, and bevacizumab (Fig. 4A) had very lim-
ited effects in preclinical and clinical studies. In con-
trast, afatinib plus cetuximab produced a meaningful
response (Janjigian et al., 2014; Regales et al., 2009).
Weihua et al. (2008) showed that not only EGFR
kinase activity but also kinase-independent functions
allow cancer cells to survive. Another recent preclinical
study using an in vitro kinase assay showed that
EGFR L858R + T790M preferentially dimerizes with
wild-type EGFR or ERBB2 on the cell surface (Red
Brewer et al., 2013). In addition, Jia et al. (2016)
showed the importance of EGFR dimerization inhibi-
tion using cetuximab for a mutant-selective allosteric
EGFR inhibitor, EA1045. These findings suggest why
afatinib plus cetuximab have a greater effect in lung
tumors harboring EGFR mutations (Regales et al.,
2009). The reasons are as follows: (a) Afatinib can
inhibit mutant EGFR and wild-type EGFR and
ERBB2 (Li et al., 2008) and (b) cetuximab is able to
block wild-type EGFR activation by interfering with
ligand binding and dimerization (Li et al., 2005).
Several clinical trials have shown the significance of
adding bevacizumab to EGFR-TKIs (Herbst et al.,
2011; Ichihara et al., 2015; Seto et al., 2014). One
mechanism of this successful combination is the
antiangiogenic effect. Another possible reason is the
improved delivery of EGFR-TKIs due to normaliza-
tion of the tumor microenvironment (Chatterjee et al.,
2014). However, in this study, the afatinib concentra-
tion was not increased in xenograft tumors. This is
consistent with other in vivo preclinical experiments
assessing the effect of bevacizumab on the erlotinib
concentration (Li et al., 2014), and is also consistent
with the finding that an increased dose of afatinib
(25 mgkg1) plus cetuximab without bevacizumab did
not induce a pathological CR in this study (Fig. 1A).
A recent report suggested that the crosstalk between
VEGFR and EGFR may be important for tumor
growth; that report showed that dual malfunction of
the EGFR and VEGFR genes resulted in complete
tumor inhibition (Lichtenberger et al., 2010). Taken
together, dual inhibition of the VEGFR and EGFR
pathways may be one of the mechanisms underlying
the induced deep remission seen in our model.
Our strategy was to use intensive dual blocking of
driver oncoproteins with TKIs and antibodies com-
bined with an antiangiogenic reagent. This strategy
has already been used in clinical trials for solid
tumors, including colon, breast, salivary gland, and
lung cancers (Falchook et al., 2013a,b,c, 2014a,b).
With the completion of these clinical studies, we expect
that a trial using afatinib, cetuximab, and bevacizumab
triplet therapy is clinically feasible. However, we would
first need to consider the toxicity of this treatment,
especially in terms of the skin rash and diarrhea that
often result from wild-type EGFR inhibition (Janjigian
et al., 2014). Second, we have to consider the negative
result of a clinical trial assessing the combination
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therapy with cytotoxic chemotherapy, cetuximab, and
bevacizumab for colorectal cancer (Tol et al., 2009).
However, we expect that dose modification could
result in treatment tolerance while still having a suffi-
cient effect.
In conclusion, we showed that triplet therapy with
afatinib, cetuximab, and bevacizumab repeatedly
induced pathological CR in lung cancers harboring
EGFR T790M mutations with tolerable toxicity in
preclinical xenograft models. The triplet therapy may
have the potential to induce deep remission and pro-
long survival in patients with lung cancers harboring
EGFR mutations. Clinical study of triplet therapy
with afatinib, cetuximab, and bevacizumab is war-
ranted.
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